NY-REN-50 antigen Antibody [PerCP]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-47502PCP
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human
Applications
ELISA, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Western Blot
Label
PerCP (Excitation = 490 nm, Emission = 675 nm)
Antibody Source
Polyclonal Rabbit IgG
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
zinc finger protein 839. (Uniprot# A8K0R7)
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Applications for NY-REN-50 antigen Antibody [PerCP]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Immunocytochemistry/ Immunofluorescence
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: NY-REN-50 antigen
Alternate Names
C14orf131, chromosome 14 open reading frame 131, FLJ11132, Renal carcinoma antigen NY-REN-50, zinc finger protein 839
Gene Symbol
ZNF839
Additional NY-REN-50 antigen Products
Product Documents for NY-REN-50 antigen Antibody [PerCP]
Product Specific Notices for NY-REN-50 antigen Antibody [PerCP]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...